Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing, 100010, China.
London Metropolitan University, London, N7 8DB, United Kingdom.
Biomed Pharmacother. 2020 Nov;131:110712. doi: 10.1016/j.biopha.2020.110712. Epub 2020 Sep 9.
Cardiovascular disease (CVD) is prevalent worldwide and remains a leading cause of death. Although substantial progress has been made in the diagnosis and treatment of CVD, the prognosis remains unsatisfactory. Renalase is a newly discovered cytokine that is synthesized by the kidney and then secreted into blood. Numerous studies have suggested the efficacy of renalase in treating CVD by metabolizing catecholamines in the circulatory system. As a new biomarker of heart disease, renalase is normally recognized as a signalling molecule that activates cytoprotective intracellular signals to lower blood pressure, protect ischaemic heart muscle and promote atherosclerotic plaque stability in CVD, which subsequently improves cardiac function. Due to its important regulatory role in the circulatory system, renalase has gradually become a potential target in the treatment of CVD. This review summarizes the structure, mechanism and function of renalase in CVD, thereby providing preclinical evidence for alternative approaches and new prospects in the development of renalase-related drugs against CVD.
心血管疾病(CVD)在全球范围内普遍存在,仍然是主要的死亡原因。尽管在 CVD 的诊断和治疗方面取得了重大进展,但预后仍然不尽人意。肾酶是一种新发现的细胞因子,由肾脏合成,然后分泌到血液中。大量研究表明,肾酶通过代谢循环系统中的儿茶酚胺在治疗 CVD 方面具有疗效。作为心脏病的一种新生物标志物,肾酶通常被认为是一种信号分子,它可以激活细胞保护的细胞内信号,降低血压,保护缺血性心肌,并促进 CVD 中动脉粥样硬化斑块的稳定性,从而改善心脏功能。由于肾酶在循环系统中具有重要的调节作用,它已逐渐成为 CVD 治疗的潜在靶点。本综述总结了肾酶在 CVD 中的结构、机制和功能,为肾酶相关药物治疗 CVD 的替代方法和新前景提供了临床前证据。